Peramavir
Total Payments
$46,528
Transactions
22
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $26,293 | 10 | 0 |
| 2018 | $20,235 | 12 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $46,528 | 22 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, randomized, open label, active-controlled study to evaluate the safety, pharmacokinetics and effectiveness of IV peramivir compared to oral oseltamivir in pediatric subjects with acute uncomplicated influenza | BioCryst Pharmaceuticals, Inc. | $46,528 | 0 |
Top Doctors Receiving Payments for Peramavir
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Shreveport, LA | $46,528 | 22 |
Ad
Manufacturing Companies
- BioCryst Pharmaceuticals, Inc. $46,528
Product Information
- Type Drug
- Total Payments $46,528
- Total Doctors 0
- Transactions 22
About Peramavir
Peramavir is a drug associated with $46,528 in payments to 0 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2018 to 2019. In 2019, $26,293 was paid across 10 transactions to 0 doctors.
The most common payment nature for Peramavir is "Unspecified" ($46,528, 100.0% of total).
Peramavir is associated with 1 research study, including "A Phase 3, randomized, open label, active-controlled study to evaluate the safety, pharmacokinetics and effectiveness of IV peramivir compared to oral oseltamivir in pediatric subjects with acute uncomplicated influenza" ($46,528).